靶向表皮生长因子受体治疗结直肠癌的耐药机制及中药研究进展
Resistance mechanism of EGFR targeted therapy for colorectal cancer and research progress of traditional Chinese herbal medicines
- 上海中医药杂志 2022年56卷第2期 页码：81-86
- 作者机构：
1.上海中医药大学附属曙光医院肿瘤科/肿瘤研究所（上海 201203）
2.上海中医药大学附属岳阳中西医结合医院肿瘤一科（上海 200437）
- 作者简介：
杨利梅，女，硕士研究生，主要从事恶性肿瘤的中医药防治工作
朱惠蓉 ，主任医师，博士研究生导师； E-mail： zhu_huirong@ 126.com
- 基金信息：国家自然科学基金项目(81874399);上海申康医院发展中心临床三年行动计划项目(SHDC2020CR4043)
DOI：10.16305/j.1007-1334.2022.2110047
中图分类号：
扫 描 看 全 文
杨利梅,张影茹,程悦蕾等.靶向表皮生长因子受体治疗结直肠癌的耐药机制及中药研究进展[J].上海中医药杂志,2022,56(02):81-86.
YANG Limei,ZHANG Yingru,CHENG Yuelei,et al.Resistance mechanism of EGFR targeted therapy for colorectal cancer and research progress of traditional Chinese herbal medicines[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):81-86.
杨利梅,张影茹,程悦蕾等.靶向表皮生长因子受体治疗结直肠癌的耐药机制及中药研究进展[J].上海中医药杂志,2022,56(02):81-86. DOI： 10.16305/j.1007-1334.2022.2110047.
YANG Limei,ZHANG Yingru,CHENG Yuelei,et al.Resistance mechanism of EGFR targeted therapy for colorectal cancer and research progress of traditional Chinese herbal medicines[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):81-86. DOI： 10.16305/j.1007-1334.2022.2110047.
摘要
综述靶向表皮生长因子受体（EGFR）治疗结直肠癌的耐药机制和中药研究进展。EGFR信号通路的分子改变和代偿性信号通路的异常激活是抗-EGFR治疗耐药发生的主要机制。中药多靶点的作用特点，使其在逆转肿瘤耐药方面具有明显优势。多种中药及其有效成分不仅具有直接抗肿瘤作用，与靶向药物联合使用还可以增强抗肿瘤西药敏感性，并克服肿瘤耐药，值得进一步深入研究。
Abstract
This article reviews the resistance mechanism of epidermal growth factor receptor （EGFR） targeted therapy for colorectal cancer and the research progress of traditional Chinese herbal medicines （TCHMs）. Molecular mutation of the EGFR signaling pathway and abnormal activation of the compensatory signaling pathway are the main mechanisms for the resistance to anti-EGFR therapy. TCHMs have shown an obvious advantage in reversing tumor drug resistance owing to their multi-targeting effects. A variety of traditional Chinese herbal medicines and their active components not only have direct anti-tumor effects， but also can enhance the sensitivity of anti-tumor drugs and inhibit tumor drug resistance when used in combination with targeted drugs， which therefore are worthy of further in-depth study.
关键词
大肠癌表皮生长因子受体靶向治疗肿瘤耐药中药研究综述
Keywords
colorectal cancerepidermal growth factor receptortargeted therapytumor drug resistancetraditional Chinese herbal medicine researchreview
references
BRAY F，FERLAY J，SOERJOMATARAM I，et al. Global cancer statistics 2018： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin，2018，68（6）：394-424.
HEINEMANN V，WEIKERSTHAL L F，DECKER T，et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer： final survival and per-protocol analysis of FIRE-3， a randomised clinical trial［J］. Br J Cancer，2021，124（3）：587-594.
CREMOLINI C， ROSSINI D， DELL'AQUILA E， et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan： a phase 2 single-arm clinical trial ［J］. JAMA Oncol，2019，5（3）：343-350.
WESTOVER D，ZUGAZAGOITIA J，CHO B C，et al. Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors［J］. ANN Oncol，2018，29（suppl 1）：i10-i19.
WANG D，LU Y，NANNAPANENI S，et al. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN［J/OL］. Oral Oncol，2021，112：105074［2021-08-16］. https：//www.sciencedirect.com/ science/article/abs/pii/S1368837520305108？via%3Dihubhttps://www.sciencedirect.com/science/article/abs/pii/S1368837520305108?via%3Dihub.
LUO H，VONG C T，CHEN H，et al. Naturally occurring anti-cancer compounds： shining from chinese herrbal medicine［J/OL］.Chin Med，2019，14：18［2021-08-16］.https：//www.ncbihttps://www.ncbi， nlm.gov/pmc/articles/PMC6836491.
FORNASIER G，FRANCESCON S，BALDO P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer： a narrative review［J］. ADV Ther， 2018， 35（10）：1497-1509.
LI Q H，WANG Y Z，TU J，et al. Anti-EGFR therapy in metastatic colorectal cancer： mechanisms and potential regimens of drug resistance［J］. Gastroenterol Rep，2020， 8（3）：179-191.
ALGARS A，SUNDSTROM J，LINTUNEN M，et al. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer ［J］. Int J Cancer，2017，140（4）：922-929.
SUNAKAWA Y， YANG D， MORAN M， et al. Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer［J］. Cancer Biol Ther，2016，17（7）：751-759.
SMYTH E C，KHAN K，CUNNINGHAM D. AREG and EREG as predictive biomarkers for RAS wild-type colorectal cancer treated with panitumumab： a fresh approach to an old puzzle［J］. JAMA Oncol，2016，2（5）：578-579.
STAHLER A，STINTZING S，MODEST D P，et al. Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer： combined analysis of three randomized trials ［J］. Clin Cancer Res，2020，26（24）：6559-6567.
SELIGMANN J F，ELLIOTT F，RICHMAN S，et al. Clinical and molecular characteristics and treatment outcomes of advanced right-colon， left-colon and rectal cancers： data from 1180 patients in a phase Ⅲ trial of panitumumab with an extended biomarker panel［J］. Ann Oncol，2020，31（8）：1021-1029.
CHANG Y Y，LIN P C，LIN H H，et al. Mutation spectra of RAS gene family in colorectal cancer［J］. Am J Surg，2016，212（3）：537-544.
YOSHINO T，ARNOLD D，TANIGUCHI H，et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer： a JSMO-ESMO initiative endorsed by CSCO， KACO， MOS， SSO and TOS ［J］. Ann Oncol，2018，29（1）：44-70 .
GOLDBERG S B，REDMAN M W，LILENBAUM R，et al. Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer： final results from SWOG S1403 ［J］. J Clin Oncol，2020，38（34）：4076-4085.
LI Z N，ZHAO L，YU L F，et al. BRAF and KRAS mutations in metastatic colorectal cancer： future perspectives for personalized therapy［J］. Gastroenterol Rep，2020，8（3）：192-205.
YAEGER R， KOTANI D， MONDACA S， et al. Response to anti-EGFR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer［J］. Clin Cancer Res，2019， 25（23）：7089-7097.
LOREE J M，DOWERS A，TU D，et al. Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial［J］. Clin Cancer Res， 2021，27（1）：52-59.
PRAHALLAD A，SUN C，HUANG S，et al. Unresponsiveness of colon cancer to BRAF（V600E） inhibition through feedback activation of EGFR［J］. Nature，2012，483（7387）：100-103.
CORCORAN R B，ANDRE T，ATREYA C E，et al. Combined BRAF， EGFR， and MEK inhibition in patients with BRAF（V600E）-mutant colorectal cancer［J］. Cancer Discov，2018，8（4）：428-443.
ROVIELLO G，D'ANGELO A，PETRIOLI R，et al. Encorafenib， binimetinib， and cetuximab in BRAF V600E-mutated colorectal cancer［J］. Transl Oncol，2019，381（17）：1632-1643.
CUTSEM E，HUIJBERTS S，GROTHEY A，et al. Binimetinib， encorafenib， and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer： safety lead-in results from the phase Ⅲ BEACON colorectal cancer study ［J］. J Clin Oncol，2019， 37（17）：1460-1469.
BOKU S，WATANABE M，SUKENO M，et al. Deactivation of glutaminolysis sensitizes PIK3CA-mutated colorectal cancer cells to aspirin-induced growth inhibition［J/OL］. Cancers，2020，12（5）：1097［2021-08-16］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC7281071https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281071.
MEI Z B，DUAN C Y，LI C B， et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer： a systematic review and meta-analysis［J］. Ann Oncol，2016，27（10）：1836-1848.
FU X，LIN H，FAN X，et al. The Spectrum， tendency and predictive value of PIK3CA mutation in Chinese colorectal cancer patients［J/OL］. Front Oncol，2021，11：595675［2021-08-16］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC8032977https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032977.
LIN P C， LIN J K， LIN H H， et al. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 （PTEN） loss in colorectal cancer ［J/OL］. World J Surg Oncol，2015，13：186［2021-08-16］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC4489205https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489205.
TEKESIN K，EMIN G M，BAYRAK S，et al. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies［J］. J Buon，2019，24（5）：1920-1926.
TURAL D，BATUR S，ERDAMAR S，et al. Analysis of PTEN， BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS［J］. Tumour Biol，2014，35（2）：1041-1049.
AGOSTON E I，MICSIK T，ACS B， et al. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas： performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity［J/OL］. Diagn Pathol， 2016，11（1）：61［2021-08-16］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC4939017https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939017.
GREALLY M， KELLY C M， CERCEK A. HER2： An emerging target in colorectal cancer［J］. Curr Probl Cancer，2018，42（6）：560-571.
DE CUYPER A，VAN DEN EYNDE M，MACHIELS J P. HER2 as a predictive biomarker and treatment target in colorectal cancer［J］. Clin Colorectal Cancer，2020，19（2）：65-72.
WANG G，HE Y，SUN Y，et al. Prevalence， prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer［J］. Clin Transl Oncol， 2020，22（6）：813-822.
LA SALVIA A，LOPEZ-GOMEZ V，GARCIA-CARBONERO R. HER2-targeted therapy： an emerging strategy in advanced colorectal cancer［J］. Expert Opin Investig Drugs，2019，28（1）：29-38.
TROIANI T，MARTINELLI E，NAPOLITANO S，et al. Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells［J］. Clin Cancer Res，2013，19（24）：6751-6765.
RAGHAV K，MORRIS V，TANG C，et al. MET amplification in metastatic colorectal cancer： an acquired response to EGFR inhibition， not a de novo phenomenon［J］. Oncotarget，2016，7（34）：54627-54631.
DELORD J P，ARGILES G，FAYETTE J，et al. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment［J］. Invest New Drugs，2020，38（6）：1774-1783.
刘嘉湘，田建辉.传承中医药学术精华，促进肿瘤学创新发展［J］.上海中医药杂志，2020， 54（7）： 29-33.
蒋海燕，张士强，杨蕴，等.基于“肺与大肠相表里”研究健脾固肠方通过调节肠道免疫平衡抑制肺癌小鼠肿瘤转移的机制［J］. 上海中医药杂志，2020， 54（3）： 91-96.
王子元，孙明瑜，陈佳，等. 健脾解毒方通过NF-κB/Nrf2/MRP2信号通路逆转结直肠癌多药耐药的作用机制［J］. 中华中医药杂志，2020， 35（7）： 3367-3371.
CAI C，WU Q，HONG H，et al. In silico identification of natural products from Traditional Chinese Medicine for cancer immunotherapy［J/OL］. Sci Rep，2021，11（1）：3332［2021-08-16］. http：//ncbi.nlm.gov /pmc/articles/PMC7870934http://ncbi.nlm.gov/pmc/articles/PMC7870934.
ABDELGAWAD M A，MUSA A，ALMALKI A H，et al. Novel phenolic compounds as potential dual EGFR and COX-2 inhibitors： design， semisynthesis， in vitro biological evaluation and in silico insights［J］. Drug Des Devel Ther，2021（15）：2325-2337.
DAI S，ZHANG G，ZHAO F，et al. Study on the molecular mechanism of the herbal couple sparganii rhizoma-curcumae rhizoma in the treatment of lung cancer based on network pharmacology［J/OL］. Evid-Based Compl Alt，2021：6664489［2021-08-16］.https：//www.ncbi.nlm. nih. gov/pmc/articles/PMC8235983https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235983.
陈琦，李雄英，唐夏焘. 榄香烯通过c-Met信号通路逆转由肝细胞生长因子诱导的吉非替尼耐药作用［J］. 中国病理生理杂志，2018， 34（3）： 469-473.
CHEN P，LI X，ZHANG R，et al. Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation［J］. Theranostics，2020，10（11）：5107-5119.
李俊，陈飞，程丹，等. 白藜芦醇逆转胃癌细胞对阿帕替尼耐药性的实验研究［J］. 临床肿瘤学杂志，2018， 23（9）： 790-794.
WANG Y，WANG W，WU X，et al. Resveratrol sensitizes colorectal cancer cells to cetuximab by connexin 43 upregulation-induced Akt inhibition［J/OL］. Front Oncol，2020，10：383［2021-08-16］.https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC7155766https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155766.
LI F， CUI H， JIN X， et al. Triptolide inhibits epithelialmesenchymal transition and induces apoptosis in gefitinibresistant lung cancer cells ［J］. Oncol Rep，2020，43（5）：1569-1579.
白利平，康向鹏，林立，等. 自噬介导的雷公藤甲素提高西妥昔单抗对SW480细胞治疗效果的实验研究［J］. 中国药理学通报，2019， 35（3）： 396-402.
MI C，CAO X，MA K，et al. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1alpha and STAT3 in KRAS mutant human colon cancer cells ［J/OL］. Chem Biol Interact，2021，351：109729［2021-08-16］. https：//www.sciencedirect.com/science/article/abs/pii/S0009279721003677？via%3Dihubhttps://www.sciencedirect.com/science/article/abs/pii/S0009279721003677?via%3Dihub.
钱俏红，陈瑞芳，李晶，等. 去甲斑蝥素通过调节Hedgehog信号通路对卵巢癌耐药细胞株肿瘤干细胞活性的影响［J］. 中华中医药杂志，2021， 36（5）： 2926-2930.
樊丽，许景伟，王晓鑫，等. 去甲斑蝥素对人未分化甲状腺癌FRO细胞增殖和凋亡的影响及机制［J］. 广西医学，2020， 42（6）： 1257-1260.
WU H，FAN F，LIU Z，et al. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway［J］. Cancer Chemother Pharmacol，2015，76（2）：307-315.
CAO F，GONG Y B，KANG X H，et al. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer［J/OL］. Toxicol Appl Pharmacol，2019，379：114662［2021-08-16］. https：//www.sciencedirect.com/science/article/pii/S0041008X19302704？via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0041008X19302704?via%3Dihub.
ZHANG Z， GUO Y， CHEN M， et al. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor［J］. Inflammopharmacology，2021，29（5）：1587-1601.
刘文虎， 袁江北， 张帆， 等. 姜黄素通过Wnt3a/β-catenin/EMT信号通路抑制胃癌细胞的增殖、迁移及侵袭［J］. 中国中药杂志，2019， 44（14）： 3107-3115.
CHEN P，HUANG H P，WANG Y，et al. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death［J/OL］. J Exp Clin Cancer Res，2019，38（1）：254［2021-08-16］. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC6567416https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567416.
LI C，WANG Z，CHEN W，et al. An integrative metabolomic and network pharmacology study revealing the regulating properties of Xihuang Pill that improves anlotinib effects in lung cancer ［J/OL］. Front Oncol，2021，11：697247［2021-08-16］. https：//www.ncbi.nlm.nih.gov/ pmc/articles/PMC8381607https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381607.
0
浏览量
665
下载量
0
CSCD
3
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70551 今日访问量：32